Orchestra BioMed Director's Trust Sells Shares to Cover Tax Obligations
Rhea-AI Filing Summary
Orchestra BioMed Holdings Director Eric S. Fain has filed a Form 144 notice for the proposed sale of 2,683 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $8,194.15.
Key details of the transaction:
- The shares were acquired on June 25, 2025, through restricted stock vesting as compensation
- The sale is planned for June 26, 2025, on NASDAQ
- The sale is being conducted to cover tax obligations from a vested equity award distribution
- The transaction will be executed through the Fain Living Trust, where Eric S. Fain serves as trustee
The filing indicates that the seller has no knowledge of undisclosed material adverse information regarding Orchestra BioMed's operations. The company currently has 38,312,512 shares outstanding.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is the reason for Eric Fain's OBIO stock sale in June 2025?
The Form 144 filing indicates that the sale is to cover a tax obligation resulting from the settlement of a vested equity award distribution. The shares were acquired through Restricted Stock Vesting on June 25, 2025, as part of compensation.